Journal of the Korean Society of Food Science and Nutrition (한국식품영양과학회지)

The Korean Society of Food Science and Nutrition (한국식품영양과학회)
권호 표지
DOI QR코드

DOI QR Code

Induction of Apoptosis by Combination Treatment with Luteolin and TRAIL in T24 Human Bladder Cancer Cells

T24 방광암세포에서 Luteolin과 TRAIL의 복합 처리에 따른 Apoptosis 유도

  • Park, Hyun Soo (School of Korean Medicine, Pusan National University) ;
  • Choi, Yung Hyun (Dept. of Biochemistry, College of Oriental Medicine, Dongeui University)
  • 박현수 (부산대학교 한의학전문대학원) ;
  • 최영현 (동의대학교 한의과대학 생화학교실)
  • Received : 2013.04.19
  • Accepted : 2013.05.16
  • Published : 2013.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis by targeting cancer cells. However, some cancer cells are resistant to TRAIL-induced cytotoxicity. One method of overcoming TRAIL resistance is combination treatment with reagents to sensitize cells to TRAIL. Luteolin, a flavonoid, has been shown to have anti-cancer effects by inducing apoptosis and cell cycle arrest in various cancer cell lines in vitro. In this study, we investigated the effects of combination treatment with non-toxic concentration of TRAIL and luteolin in T24 human bladder cancer cells. Combined treatment with luteolin and TRAIL significantly inhibits cell proliferation via activation of caspases by inducing Bid truncation, up-regulation of Bax and down-regulation of X-linked inhibitor of apoptosis protein (XIAP). However, the apoptotic effects of combination treatment with luteolin and TRAIL were significantly inhibited by specific caspases inhibitors. Taken together, these results indicate that combination treatment with TRAIL and luteolin can induce apoptosis in TRAIL-resistant cancer cells through down-regulation of XIAP and modulation of tBid and Bax expression.

본 연구에서는 플라보노이드 계열 중의 하나인 luteolin을 이용하여 TRAIL에 저항성을 가지는 T24 방광암세포에서 TRAIL 저항성 극복 가능성을 조사하였다. 본 연구의 결과에 의하면 luteolin 및 TRAIL 각각 단독 처리 시 세포증식에 전혀 영향을 미치지 못한 농도의 복합 처리 시 세포증식억제 효과가 크게 증가하였음 알 수 있었다. 이러한 증식억제와 연관된 aspoptosis 유도는 caspase-8의 활성화에 의한 tBid의 발현 증가와 pro-apoptotic 인자인 Bax의 발현 증가로 인한 caspase-9 및 -3의 활성화로 이어지는 type II apoptosis에 의한 것이라 추측되며, 이러한 가정은 각각의 caspase 선택적 저해제를 이용하여 재확인 하였다. 본 연구결과는 TRAIL에 저항성을 보이는 암세포에 luteolin이 감수성을 높이는데 효과적일 수 있으며, 암세포에 대한 combination therapy를 위한 기초자료로 활용성이 높을 것으로 사료된다.

Keywords

References

  1. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, Sesterhenn IA, Tachibana M, Weider J. 2005. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66: 4-34. https://doi.org/10.1016/S0090-4295(05)00945-3
  2. Nargund VH, Tanabalan CK, Kabir MN. 2012. Management of non-muscle-invasive (superficial) bladder cancer. Semin Oncol 39: 559-572. https://doi.org/10.1053/j.seminoncol.2012.08.001
  3. Smaldone MC, Jacobs BL, Smaldone AM, Hrebinko RL Jr. 2008. Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urology 72: 613-616. https://doi.org/10.1016/j.urology.2008.04.052
  4. Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha AA, Natale C, Santacroce R, Di Corcia MG, Lucchese A, Dini L, Pani P, Santacroce S, Simone S, Bucci R, Farber E. 2002. Cell death: apoptosis versus necrosis (review). Int J Oncol 21: 165-170.
  5. Han SI, Kim YS, Kim TH. 2008. Role of apoptotic and necrotic cell death under physiologic conditions. BMB Rep 41: 1-10. https://doi.org/10.5483/BMBRep.2008.41.1.001
  6. Elmore S. 2007. Apoptosis: a review of programmed cell death. Toxicol Pathol 35: 495-516. https://doi.org/10.1080/01926230701320337
  7. Lowe SW, Lin AW. 2000. Apoptosis in cancer. Carcinogenesis 21: 485-495. https://doi.org/10.1093/carcin/21.3.485
  8. Riedl SJ, Shi Y. 2004. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5: 897-907. https://doi.org/10.1038/nrm1496
  9. Le Marchand L. 2002. Cancer preventive effects of flavonoids-a review. Biomed Pharmacother 56: 296-301. https://doi.org/10.1016/S0753-3322(02)00186-5
  10. Arts IC. 2008. A review of the epidemiological evidence on tea, flavonoids, and lung cancer. J Nutr 138: 1561S-1566S.
  11. Romagnolo DF, Selmin OI. 2012. Flavonoids and cancer prevention: a review of the evidence. J Nutr Gerontol Geriatr 31: 206-238. https://doi.org/10.1080/21551197.2012.702534
  12. Seelinger G, Merfort I, Schempp CM. 2008. Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta Med 74: 1667-1677. https://doi.org/10.1055/s-0028-1088314
  13. Lee HJ, Wang CJ, Kuo HC, Chou FP, Jean LF, Tseng TH. 2005. Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK. Toxicol Appl Pharmacol 203:124-131. https://doi.org/10.1016/j.taap.2004.08.004
  14. Yang SF, Yang WE, Chang HR, Chu SC, Hsieh YS. 2008. Luteolin induces apoptosis in oral squamous cancer cells. J Dent Res 87: 401-406. https://doi.org/10.1177/154405910808700413
  15. Park SH, Park HS, Lee JH, Chi GY, Kim GY, Moon SK, Chang YC, Hyun JW, Kim WJ, Choi YH. 2013. Induction of endoplasmic reticulum stress-mediated apoptosis and non-canonical autophagy by luteolin in NCI-H460 lung carcinoma cells. Food Chem Toxicol 56: 100-109. https://doi.org/10.1016/j.fct.2013.02.022
  16. Ou YC, Kuan YH, Li JR, Raung SL, Wang CC, Hung YY, Chen CJ. 2012. Induction of apoptosis by luteolin involving akt inactivation in human 786-o renal cell carcinoma cells. J Evidence-Based Complementary Altern Med Vol 2013, Article ID 109105.
  17. Pratheeshkumar P, Son YO, Budhraja A, Wang X, Ding S, Wang L, Hitron A, Lee JC, Kim D, Divya SP, Chen G, Zhang Z, Luo J, Shi X. 2012. Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. PLoS One 7: e52279. doi: 10.1371/journal.pone.0052279.
  18. Shi RX, Ong CN, Shen HM. 2005. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res 65: 7815-7823. https://doi.org/10.1158/0008-5472.CAN-04-3875
  19. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M, Nakanishi R, Nishino H, Sakai T. 2005. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. Biochem Biophys Res Commun 333: 833-838. https://doi.org/10.1016/j.bbrc.2005.05.179
  20. Yan J, Wang Q, Zheng X, Sun H, Zhou Y, Li D, Lin Y, Wang X. 2012. Luteolin enhances TNF-related apoptosis-inducing ligand's anticancer activity in a lung cancer xenograft mouse model. Biochem Biophys Res Commun 417: 842-846. https://doi.org/10.1016/j.bbrc.2011.12.055
  21. Almasan A, Ashkenazi A. 2003. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14: 337-348. https://doi.org/10.1016/S1359-6101(03)00029-7
  22. Holoch PA, Griffith TS. 2009. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 625: 63-72. https://doi.org/10.1016/j.ejphar.2009.06.066
  23. Steinwede K, Henken S, Bohling J, Maus R, Ueberberg B, Brumshagen C, Brincks EL, Griffith TS, Welte T, Maus UA. 2012. TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. J Exp Med 209: 1937-1952. https://doi.org/10.1084/jem.20120983
  24. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. 2007. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39: 1462-1475. https://doi.org/10.1016/j.biocel.2007.02.007
  25. Zhang L, Fang B. 2005. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12:228-237. https://doi.org/10.1038/sj.cgt.7700792

Cited by

  1. Combination of oncolytic adenovirus and luteolin exerts synergistic antitumor effects in colorectal cancer cells and a mouse model vol.16, pp.6, 2017, https://doi.org/10.3892/mmr.2017.7784